<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813721</url>
  </required_header>
  <id_info>
    <org_study_id>20110146</org_study_id>
    <nct_id>NCT01813721</nct_id>
  </id_info>
  <brief_title>Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.</brief_title>
  <official_title>Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% - 20%) Febrile Neutropenia Risk.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational study investigating how physicians assess the risk of
      febrile neutropenia (FN) developing in patients who will receive chemotherapy.

      Approximately 150-200 investigators will take part in about 100 sites in Europe, Canada and
      Australia. Approximately 1000 subjects will be studied, all of whom will have non-small cell
      lung cancer (NSCLC), small cell lung cancer (SCLC), non-Hodgkin's lymphoma (NHL) or breast
      cancer and will be due to receive one of the specific chemotherapy regimens of interest.

      Investigators' approach to FN risk assessment will be studied using lists of possible risk
      factors they may consider during their assessment. Investigators will be asked to select and
      rank the factors they consider the most important when assessing the overall FN risk of a
      subject and when making the decision whether to treat with granulocyte-colony stimulating
      factor (G-CSF) primary prophylaxis (PP). They will be asked to make these selections based
      initially on their own routine clinical practise and subsequently relating specifically to
      each subject recruited.

      This is a non-interventional study that involves no procedures outside normal care for the
      subjects; all data collection will be completed prior to chemotherapy administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although a formal hypothesis will not be tested in this observational study, it is
      hypothesized that the clinical risk factors ranked as the most important when conducting FN
      risk assessments by investigators are aligned with international guidelines and published
      data. Also, that the investigator's decision to treat with G-CSF PP is influenced by clinical
      and non-clinical risk factors (such as distance from site, estimated subject compliance, and
      access to fully reimbursed G-CSF).

      Study Design: Prior to identifying eligible subjects, Investigators will be registered and
      will record baseline information. During this Baseline Investigator Assessment investigators
      will be provided with two lists of risk factors. Investigators must rank selected risk
      factors that they consider to be the most important when assessing 1) overall FN risk (only
      scientific factors will be included), and 2) when deciding on whether G-CSF PP treatment will
      be used or not (this list will also contain non clinical factors). They will also record
      their own FN risk intervention threshold, which is the FN risk threshold score at which they
      would use G-CSF PP in their usual clinical practice.

      Investigators will then prospectively and sequentially identify eligible subjects with NHL,
      breast or lung cancer who are due to initiate one of the permitted standard dose chemotherapy
      regimens listed in the protocol. The permitted chemotherapy regimens have an estimated
      intermediate FN risk (10%-20%) documented in published data and/or international guidelines.

      For each enrolled subject, Investigators will complete a Subject Assessment prior to the
      start of their chemotherapy. They will be provided with the same two lists of risk factors as
      in the Baseline Assessment and asked to complete them based on each specific subject.
      Investigators must rank selected risk factors that they consider to be the most important
      when assessing 1) overall FN risk (only scientific factors will be included), and 2) when
      deciding on whether G-CSF PP treatment will be used or not. They will also document their
      final estimated FN risk score as a percentage based on the subject's medical history and
      standard of care (SOC) assessments (their routine practice for assessing this risk), and a
      decision as to whether G-CSF PP will be administered. Investigators will record which type of
      G-CSF they plan to use if one will be used.

      End of Study for a subject will occur once these activities have been completed, and a
      prescription for the first cycle of chemotherapy has been written. The subject data collected
      will only be historical subject information and laboratory data from SOC assessments
      performed prior to beginning chemotherapy treatment. No data will be collected after the
      initiation of chemotherapy.

      The approach to the statistical analysis will be generally descriptive in nature. The primary
      analysis will be conducted at two levels; investigator level and the subject level. It is
      expected that the opinions of investigators at a single site (that is, a department within a
      cancer treatment centre) will be correlated. Also, that the opinions about subjects from a
      single investigator will be more alike than subjects of other investigators; adjustments will
      be made in the analyses to account for this. Confidence intervals for the investigator level
      analysis and the subject level data will obtained from Multi-level Modelling (MLM) to allow
      for the expected intra-site and intra-investigator correlation of investigators within sites
      and subjects within investigator. In general, categorical data will be summarised by the
      number and percentage of subjects in each category. Continuous data will be summarised by
      mean, standard deviation, median, lower and upper quartiles, minimum and maximum values.
      Two-sided exact 95% confidence intervals (obtained using MLM) will be presented, where
      appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia</measure>
    <time_frame>Baseline (prior to participant enrolment)</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the risk factors that they considered to be the most important when assessing overall febrile neutropenia (FN) risk. Age and chemotherapy regimen were specified in the protocol as risk factors of interest. Reported are age and chemotherapeutic agents ranked individually, chemotherapy agents detailed by specific factors, and age and chemotherapy agents jointly ranked. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia (FN)</measure>
    <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet and asked to rank the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants for Whom Age and Chemotherapy Regimen Were Ranked as an Important Risk Factor</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation</time_frame>
    <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment were collected in this study. Age and chemotherapy regimen were specified in the protocol as risk factors of interest. Reported are age and chemotherapeutic agents ranked individually, chemotherapy agents detailed by specific factors, and age and chemotherapy agents jointly ranked. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important</measure>
    <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Clinical Specialty</measure>
    <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group. Subgroup analyses were performed where a subgroup contained at least 40 investigators. Results are reported for medical oncologists as this was the only specialty that contained at least 40 investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology</measure>
    <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. Subgroup analyses were performed where a subgroup contained at least 40 investigators. ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Institution Type</measure>
    <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. Subgroup analyses were performed where a subgroup contained at least 40 investigators. ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each Factor Was Ranked in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>For each participant, the investigator ranked the factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Country</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Clinical Specialty</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Institution Type</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Tumor Type</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Clinical Specialty</measure>
    <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rankt the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group. Subgroup analyses were performed where a subgroup contained at least 40 investigators. Results are reported for medical oncologists as this was the only specialty that contained at least 40 investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Number of Years in Clinical Practice in Oncology / Hematology</measure>
    <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Institution Type</measure>
    <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
    <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Country</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Clinical Specialty</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Number of Years in Clinical Practice in Oncology / Hematology</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Institution Type</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Tumor Type</measure>
    <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
    <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Investigator-assessed FN Risk at or Above the Investigator Self-reported FN-risk Intervention Threshold Who Were Planned to Receive G-CSF PP</measure>
    <time_frame>At Baseline and at enrolment, prior to chemotherapy initiation.</time_frame>
    <description>At Baseline investigators recorded the FN risk threshold score at which they would use G-CSF PP in their usual clinical practice. For each enrolled participant, the investigator documented their final estimated FN risk score as a percentage based on the participant's medical history and standard of care assessments (their routine practice for assessing this risk), and a decision as to whether G-CSF PP would be administered in Cycle 1.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1007</enrollment>
  <condition>Chemotherapy-induced Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>All patients enrolled</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible subjects will have NHL, breast or lung cancer and be due to initiate one of the
        permitted standard dose chemotherapy regimens listed in the protocol (those with a
        documented intermediate FN risk of 10-20%). Subjects will be prospectively and sequentially
        identified by approximately 150-200 investigators during their clinics distribututed in 11
        countries.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Any stage NHL, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), or
             breast cancer initiating a new chemotherapy course

          -  Scheduled to receive one of the permitted standard dose chemotherapy regimens with an
             estimated intermediate (10%-20%) FN risk according to published data or guidelines
             (planned dose modifications +/-10% are allowable).

          -  Before any study-specific procedure, the appropriate written informed consent must be
             obtained where this is required by local regulations

        Exclusion Criteria:

          -  Ongoing or planned concurrent participation in any clinical study involving
             Investigational Product that has not been approved by the European Medicines Agency
             (EMA) or competent authority for any indication,

          -  Ongoing or planned concurrent participation in any clinical study where the
             administration of Colony Stimulating Factor (CSF) is determined by the protocol
             (clinical trials on an approved drug and observational trials are permitted as long as
             these do not mandate how neutropenia should be treated)

          -  Prior stem-cell transplantation (includes bone marrow transplantation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shepparton</city>
        <state>Victoria</state>
        <zip>3630</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eggenburg</city>
        <zip>3730</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alès Cédex</city>
        <zip>30103</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Besançon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montluçon</city>
        <zip>03100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neuilly sur Seine</city>
        <zip>92202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nimes Cedex 2</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulon Cedex</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villefranche Sur Saone Cedex</city>
        <zip>69400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neustadt/Sachsen</city>
        <zip>01844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Twistringen</city>
        <zip>27239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chania</city>
        <zip>73300</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nea Kifissia, Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monza (MB)</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-722</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braila</city>
        <zip>810325</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500052</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400352</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Focsani</city>
        <zip>620165</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Onesti</city>
        <zip>601048</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pitesti</city>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suceava</city>
        <zip>720237</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huelva</city>
        <state>Andalucía</state>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucía</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La laguna</city>
        <state>Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avila</city>
        <state>Castilla León</state>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla León</state>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng SL, Wong ZW, Salar A, Steger G, Abdelsalam M, DeCosta L, Szabo Z. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. Med Oncol. 2015 Oct;32(10):236. doi: 10.1007/s12032-015-0682-z. Epub 2015 Aug 28.</citation>
    <PMID>26315712</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <results_first_submitted>December 4, 2014</results_first_submitted>
  <results_first_submitted_qc>December 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2014</results_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was enrolled on 13 December 2012 and the last patient enrolled on 08 January 2014.
There were 205 registered investigators, 35 of whom did not enrol any participants and 5 who did not enrol any eligible participants and were excluded from the primary analysis set - investigators (PASI).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Enrolled Patients</title>
          <description>Participants with cancer who were planning to receive standard dose chemotherapy regimens with a documented intermediate risk (10% to 20%) of febrile neutropenia (FN).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1007">Indicates number of participants enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="943"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Primary Analysis Set (PAS) is the set of all participants who satisfy the eligibility criteria and had at least one FN risk factor ranked by the investigator in their Subject Assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Primary Analysis Set</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="944"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="554"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-small cell lung cancer (NSCLC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin’s lymphoma (NHL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small-cell lung cancer (SCLC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator Specialty</title>
          <description>Data provided for the Primary analysis Set-Investigators, consisting of the 165 investigators who contributed participants to the primary analysis set.</description>
          <units>investigators</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Medical Oncologist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonologist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation Oncologist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Gynecologist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gynecological Surgeon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of years in oncology/hematology clinical practice</title>
          <units>investigators</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt; 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤ 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the risk factors that they considered to be the most important when assessing overall febrile neutropenia (FN) risk. Age and chemotherapy regimen were specified in the protocol as risk factors of interest. Reported are age and chemotherapeutic agents ranked individually, chemotherapy agents detailed by specific factors, and age and chemotherapy agents jointly ranked. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.</description>
        <time_frame>Baseline (prior to participant enrolment)</time_frame>
        <population>Primary analysis set - investigators (PASI), which consists of investigators who contributed participants to the primary analysis set (PAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Set - Investigators</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the risk factors that they considered to be the most important when assessing overall febrile neutropenia (FN) risk. Age and chemotherapy regimen were specified in the protocol as risk factors of interest. Reported are age and chemotherapeutic agents ranked individually, chemotherapy agents detailed by specific factors, and age and chemotherapy agents jointly ranked. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.</description>
          <population>Primary analysis set - investigators (PASI), which consists of investigators who contributed participants to the primary analysis set (PAS).</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" lower_limit="64.4" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" lower_limit="81.7" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anthracyclines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="31.6" upper_limit="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taxanes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="17.7" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platinum(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="15.1" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkylating agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="14.7" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topoisomerase II inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="8.8" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topoisomerase I inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="6.8" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gemcitabine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="5.9" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vinorelbine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="5.4" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.9" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age and chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" lower_limit="57.0" upper_limit="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia (FN)</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet and asked to rank the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group</description>
        <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators (PASI), which consists of investigators who contributed participants to the primary analysis set (PAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Set - Investigators</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia (FN)</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet and asked to rank the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group</description>
          <population>Primary analysis set - investigators (PASI), which consists of investigators who contributed participants to the primary analysis set (PAS).</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" lower_limit="81.7" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="75.7" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" lower_limit="67.9" upper_limit="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" lower_limit="64.4" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="62.4" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="60.0" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="55.6" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="54.9" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="53.0" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="53.5" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" lower_limit="51.7" upper_limit="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="52.8" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="41.1" upper_limit="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="40.2" upper_limit="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="38.2" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" lower_limit="36.6" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="32.4" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" lower_limit="32.5" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" lower_limit="27.7" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="18.2" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="15.7" upper_limit="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="1.9" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.9" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants for Whom Age and Chemotherapy Regimen Were Ranked as an Important Risk Factor</title>
        <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment were collected in this study. Age and chemotherapy regimen were specified in the protocol as risk factors of interest. Reported are age and chemotherapeutic agents ranked individually, chemotherapy agents detailed by specific factors, and age and chemotherapy agents jointly ranked. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation</time_frame>
        <population>Primary analysis set which consists of all participants who satisfied the eligibility criteria and had at least one FN risk factor ranked by the investigator in their Subject Assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Set</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Age and Chemotherapy Regimen Were Ranked as an Important Risk Factor</title>
          <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment were collected in this study. Age and chemotherapy regimen were specified in the protocol as risk factors of interest. Reported are age and chemotherapeutic agents ranked individually, chemotherapy agents detailed by specific factors, and age and chemotherapy agents jointly ranked. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.</description>
          <population>Primary analysis set which consists of all participants who satisfied the eligibility criteria and had at least one FN risk factor ranked by the investigator in their Subject Assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" lower_limit="31.9" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="88.0" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anthracyclines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" lower_limit="25.6" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taxanes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="11.6" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platinum(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="6.4" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkylating agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.4" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topoisomerase II inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.7" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vinorelbine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.1" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topoisomerase I inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gemcitabine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important</title>
        <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Set</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important</title>
          <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="88.0" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="60.7" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" lower_limit="48.1" upper_limit="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="33.7" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" lower_limit="31.9" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="23.7" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="21.2" upper_limit="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="12.7" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="12.3" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="11.1" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="10.2" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="11.5" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="5.8" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="4.1" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="3.6" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="2.9" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.7" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.8" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.4" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.4" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.3" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.1" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.4" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Investigators Who Ranked Each Factor in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Set - Investigators</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set - investigators</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="82.6" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" lower_limit="70.6" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="64.3" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="61.2" upper_limit="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="60.8" upper_limit="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" lower_limit="56.2" upper_limit="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="40.8" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" lower_limit="39.0" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" lower_limit="25.6" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" lower_limit="25.4" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="22.7" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="16.8" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="15.4" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="14.5" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="13.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="10.8" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="8.3" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="6.3" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="4.9" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="3.3" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Clinical Specialty</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group. Subgroup analyses were performed where a subgroup contained at least 40 investigators. Results are reported for medical oncologists as this was the only specialty that contained at least 40 investigators.</description>
        <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators; analysis only includes subgroups with at least 40 investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Oncologist</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Clinical Specialty</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group. Subgroup analyses were performed where a subgroup contained at least 40 investigators. Results are reported for medical oncologists as this was the only specialty that contained at least 40 investigators.</description>
          <population>Primary analysis set - investigators; analysis only includes subgroups with at least 40 investigators.</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="662"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" lower_limit="80.6" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="69.1" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" lower_limit="66.6" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="65.2" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="61.5" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="58.2" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" lower_limit="39.2" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="34.7" upper_limit="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" lower_limit="28.8" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="25.7" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="19.4" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="18.3" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" lower_limit="16.4" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="15.2" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="14.6" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="9.6" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="7.7" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="5.9" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="4.8" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="3.4" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. Subgroup analyses were performed where a subgroup contained at least 40 investigators. ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators; analysis only includes subgroups with at least 40 investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>≤ 10 Years</title>
          </group>
          <group group_id="O2">
            <title>&gt; 10 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. Subgroup analyses were performed where a subgroup contained at least 40 investigators. ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set - investigators; analysis only includes subgroups with at least 40 investigators.</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="687"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="70.6" upper_limit="93.4"/>
                    <measurement group_id="O2" value="90.2" lower_limit="82.9" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="61.3" upper_limit="90.2"/>
                    <measurement group_id="O2" value="79.4" lower_limit="69.0" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" lower_limit="61.6" upper_limit="87.6"/>
                    <measurement group_id="O2" value="66.8" lower_limit="56.0" upper_limit="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="52.2" upper_limit="82.6"/>
                    <measurement group_id="O2" value="74.2" lower_limit="63.6" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="46.7" upper_limit="78.8"/>
                    <measurement group_id="O2" value="71.9" lower_limit="62.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" lower_limit="37.9" upper_limit="73.7"/>
                    <measurement group_id="O2" value="69.7" lower_limit="58.6" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="39.2" upper_limit="71.6"/>
                    <measurement group_id="O2" value="46.7" lower_limit="34.9" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="31.2" upper_limit="65.6"/>
                    <measurement group_id="O2" value="51.2" lower_limit="40.6" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="24.7" upper_limit="60.0"/>
                    <measurement group_id="O2" value="27.4" lower_limit="19.5" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="23.6" upper_limit="57.1"/>
                    <measurement group_id="O2" value="32.4" lower_limit="23.7" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="21.7" upper_limit="52.1"/>
                    <measurement group_id="O2" value="33.7" lower_limit="24.1" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="16.9" upper_limit="45.8"/>
                    <measurement group_id="O2" value="20.7" lower_limit="12.7" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" lower_limit="17.0" upper_limit="45.1"/>
                    <measurement group_id="O2" value="22.4" lower_limit="14.9" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="12.9" upper_limit="41.5"/>
                    <measurement group_id="O2" value="18.3" lower_limit="11.5" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="10.9" upper_limit="36.2"/>
                    <measurement group_id="O2" value="20.6" lower_limit="13.8" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="10.9" upper_limit="36.2"/>
                    <measurement group_id="O2" value="11.5" lower_limit="6.2" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="10.6" upper_limit="36.6"/>
                    <measurement group_id="O2" value="15.4" lower_limit="9.8" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="6.6" upper_limit="29.2"/>
                    <measurement group_id="O2" value="6.6" lower_limit="3.1" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="5.3" upper_limit="26.8"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1.9" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="4.0" upper_limit="24.4"/>
                    <measurement group_id="O2" value="10.3" lower_limit="5.8" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O2" value="0.9" lower_limit="0.1" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Institution Type</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. Subgroup analyses were performed where a subgroup contained at least 40 investigators. ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>Assessed at baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators; analysis only includes subgroups with at least 40 investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>University Hospital</title>
          </group>
          <group group_id="O2">
            <title>General Hospital</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Institution Type</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. Subgroup analyses were performed where a subgroup contained at least 40 investigators. ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set - investigators; analysis only includes subgroups with at least 40 investigators.</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="79.2" upper_limit="97.2"/>
                    <measurement group_id="O2" value="84.8" lower_limit="70.4" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="56.5" upper_limit="90.1"/>
                    <measurement group_id="O2" value="71.8" lower_limit="54.4" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" lower_limit="54.8" upper_limit="88.3"/>
                    <measurement group_id="O2" value="89.0" lower_limit="70.9" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" lower_limit="50.2" upper_limit="86.7"/>
                    <measurement group_id="O2" value="65.1" lower_limit="46.5" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" lower_limit="45.6" upper_limit="83.1"/>
                    <measurement group_id="O2" value="73.9" lower_limit="58.6" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" lower_limit="50.4" upper_limit="79.2"/>
                    <measurement group_id="O2" value="71.5" lower_limit="45.9" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="36.2" upper_limit="76.5"/>
                    <measurement group_id="O2" value="47.7" lower_limit="31.2" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="27.8" upper_limit="69.2"/>
                    <measurement group_id="O2" value="51.3" lower_limit="34.4" upper_limit="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="20.5" upper_limit="59.6"/>
                    <measurement group_id="O2" value="25.9" lower_limit="13.9" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" lower_limit="20.3" upper_limit="50.7"/>
                    <measurement group_id="O2" value="30.7" lower_limit="15.0" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="15.9" upper_limit="49.1"/>
                    <measurement group_id="O2" value="43.2" lower_limit="28.2" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="11.9" upper_limit="38.4"/>
                    <measurement group_id="O2" value="15.2" lower_limit="7.1" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="10.8" upper_limit="37.3"/>
                    <measurement group_id="O2" value="38.3" lower_limit="19.8" upper_limit="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" lower_limit="9.1" upper_limit="38.3"/>
                    <measurement group_id="O2" value="23.9" lower_limit="13.3" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="8.7" upper_limit="35.8"/>
                    <measurement group_id="O2" value="19.5" lower_limit="7.8" upper_limit="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="7.9" upper_limit="34.8"/>
                    <measurement group_id="O2" value="19.6" lower_limit="10.1" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="5.9" upper_limit="31.4"/>
                    <measurement group_id="O2" value="15.0" lower_limit="6.5" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.9" upper_limit="22.7"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.0" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="2.8" upper_limit="20.9"/>
                    <measurement group_id="O2" value="15.2" lower_limit="7.1" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="1.8" upper_limit="18.1"/>
                    <measurement group_id="O2" value="8.4" lower_limit="2.4" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O2" value="2.2" lower_limit="0.3" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each Factor Was Ranked in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important</title>
        <description>For each participant, the investigator ranked the factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Set</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each Factor Was Ranked in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important</title>
          <description>For each participant, the investigator ranked the factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not. To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="944"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" lower_limit="71.4" upper_limit="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" lower_limit="53.4" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" lower_limit="59.0" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" lower_limit="42.9" upper_limit="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" lower_limit="27.8" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="12.9" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="8.5" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="5.7" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="5.3" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="4.7" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.4" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="2.9" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.7" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.8" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.9" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.2" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Country</title>
        <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set; subgroup analyses were only performed on subgroups (countries) with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Poland</title>
          </group>
          <group group_id="O2">
            <title>Greece</title>
          </group>
          <group group_id="O3">
            <title>Romania</title>
          </group>
          <group group_id="O4">
            <title>France</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Country</title>
          <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set; subgroup analyses were only performed on subgroups (countries) with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="30.4" upper_limit="74.7"/>
                    <measurement group_id="O2" value="60.3" lower_limit="33.3" upper_limit="82.2"/>
                    <measurement group_id="O3" value="91.2" lower_limit="82.4" upper_limit="95.8"/>
                    <measurement group_id="O4" value="74.5" lower_limit="64.0" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" lower_limit="38.1" upper_limit="96.2"/>
                    <measurement group_id="O2" value="39.5" lower_limit="13.8" upper_limit="72.7"/>
                    <measurement group_id="O3" value="87.2" lower_limit="56.6" upper_limit="97.3"/>
                    <measurement group_id="O4" value="82.5" lower_limit="40.1" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6" lower_limit="35.3" upper_limit="83.7"/>
                    <measurement group_id="O2" value="46.8" lower_limit="27.9" upper_limit="66.7"/>
                    <measurement group_id="O3" value="81.0" lower_limit="59.1" upper_limit="92.6"/>
                    <measurement group_id="O4" value="64.6" lower_limit="42.3" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" lower_limit="40.8" upper_limit="76.4"/>
                    <measurement group_id="O2" value="57.8" lower_limit="36.2" upper_limit="76.8"/>
                    <measurement group_id="O3" value="54.2" lower_limit="28.1" upper_limit="78.2"/>
                    <measurement group_id="O4" value="38.0" lower_limit="20.9" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" lower_limit="37.0" upper_limit="89.7"/>
                    <measurement group_id="O2" value="39.7" lower_limit="20.7" upper_limit="62.5"/>
                    <measurement group_id="O3" value="34.6" lower_limit="12.3" upper_limit="66.5"/>
                    <measurement group_id="O4" value="30.1" lower_limit="18.4" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="11.3" upper_limit="41.5"/>
                    <measurement group_id="O2" value="9.7" lower_limit="3.3" upper_limit="25.2"/>
                    <measurement group_id="O3" value="39.0" lower_limit="20.9" upper_limit="60.7"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.9" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.7" upper_limit="8.4"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5.6" upper_limit="51.5"/>
                    <measurement group_id="O3" value="25.8" lower_limit="8.2" upper_limit="57.4"/>
                    <measurement group_id="O4" value="5.6" lower_limit="1.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="2.8" upper_limit="15.4"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O3" value="11.3" lower_limit="1.7" upper_limit="48.7"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.8" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.4" upper_limit="8.5"/>
                    <measurement group_id="O2" value="21.7" lower_limit="6.0" upper_limit="54.4"/>
                    <measurement group_id="O3" value="10.9" lower_limit="3.4" upper_limit="30.0"/>
                    <measurement group_id="O4" value="2.3" lower_limit="0.3" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="14.3" lower_limit="8.0" upper_limit="24.3"/>
                    <measurement group_id="O3" value="23.7" lower_limit="10.7" upper_limit="44.5"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.1" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.4" upper_limit="9.0"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="8.0" lower_limit="2.4" upper_limit="24.0"/>
                    <measurement group_id="O4" value="10.0" lower_limit="4.2" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.3" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.6" upper_limit="15.2"/>
                    <measurement group_id="O3" value="8.6" lower_limit="2.1" upper_limit="28.7"/>
                    <measurement group_id="O4" value="7.4" lower_limit="1.5" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.2" upper_limit="11.2"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O3" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O4" value="2.1" lower_limit="0.4" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0.7" upper_limit="10.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.4" upper_limit="5.1"/>
                    <measurement group_id="O3" value="15.5" lower_limit="2.9" upper_limit="52.8"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.1" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="3.6"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.0" upper_limit="11.2"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.3" upper_limit="13.8"/>
                    <measurement group_id="O4" value="4.4" lower_limit="0.6" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="4.7"/>
                    <measurement group_id="O2" value="5.3" lower_limit="2.1" upper_limit="13.1"/>
                    <measurement group_id="O3" value="5.7" lower_limit="1.7" upper_limit="17.6"/>
                    <measurement group_id="O4" value="2.5" lower_limit="0.8" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.8" upper_limit="6.4"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O3" value="5.0" lower_limit="1.0" upper_limit="21.2"/>
                    <measurement group_id="O4" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.3" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.3" upper_limit="4.6"/>
                    <measurement group_id="O3" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O4" value="2.1" lower_limit="0.4" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.9" upper_limit="7.9"/>
                    <measurement group_id="O2" value="4.4" lower_limit="0.7" upper_limit="22.2"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.1" upper_limit="5.0"/>
                    <measurement group_id="O4" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.4" upper_limit="5.1"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.3" upper_limit="4.6"/>
                    <measurement group_id="O3" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O4" value="0.8" lower_limit="0.1" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O2" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O3" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O4" value="1.1" lower_limit="0.1" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Clinical Specialty</title>
        <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Oncologist</title>
          </group>
          <group group_id="O2">
            <title>Hematologist</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Clinical Specialty</title>
          <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="662"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" lower_limit="71.5" upper_limit="86.1"/>
                    <measurement group_id="O2" value="78.6" lower_limit="58.2" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="58.4" upper_limit="83.3"/>
                    <measurement group_id="O2" value="33.3" lower_limit="12.8" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="59.6" upper_limit="78.4"/>
                    <measurement group_id="O2" value="65.7" lower_limit="50.8" upper_limit="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" lower_limit="39.9" upper_limit="60.5"/>
                    <measurement group_id="O2" value="74.0" lower_limit="61.8" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" lower_limit="26.2" upper_limit="50.6"/>
                    <measurement group_id="O2" value="40.3" lower_limit="29.1" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="13.3" upper_limit="27.5"/>
                    <measurement group_id="O2" value="25.2" lower_limit="12.7" upper_limit="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="5.9" upper_limit="16.4"/>
                    <measurement group_id="O2" value="24.0" lower_limit="11.9" upper_limit="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="5.5" upper_limit="17.5"/>
                    <measurement group_id="O2" value="18.8" lower_limit="5.8" upper_limit="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="4.5" upper_limit="13.4"/>
                    <measurement group_id="O2" value="16.1" lower_limit="8.4" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="5.4" upper_limit="14.7"/>
                    <measurement group_id="O2" value="8.2" lower_limit="3.8" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="17.9" lower_limit="7.2" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="2.3" upper_limit="8.9"/>
                    <measurement group_id="O2" value="8.6" lower_limit="3.9" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.0" upper_limit="7.4"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.1" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.1" upper_limit="10.2"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.3" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.6" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="1.8" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.9" upper_limit="5.9"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.1" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.9" upper_limit="3.6"/>
                    <measurement group_id="O2" value="5.9" lower_limit="2.0" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.2" upper_limit="4.2"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.1" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.1" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.1" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology</title>
        <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>≤ 10 Years</title>
          </group>
          <group group_id="O2">
            <title>&gt; 10 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology</title>
          <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" lower_limit="60.4" upper_limit="87.5"/>
                    <measurement group_id="O2" value="76.8" lower_limit="69.7" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" lower_limit="35.9" upper_limit="79.2"/>
                    <measurement group_id="O2" value="65.2" lower_limit="50.5" upper_limit="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="42.9" upper_limit="71.1"/>
                    <measurement group_id="O2" value="71.1" lower_limit="62.0" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="38.5" upper_limit="70.8"/>
                    <measurement group_id="O2" value="50.2" lower_limit="41.7" upper_limit="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="18.0" upper_limit="42.6"/>
                    <measurement group_id="O2" value="40.2" lower_limit="30.9" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="8.7" upper_limit="24.3"/>
                    <measurement group_id="O2" value="18.6" lower_limit="12.8" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="8.6" upper_limit="29.6"/>
                    <measurement group_id="O2" value="12.5" lower_limit="7.6" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="3.4" upper_limit="17.1"/>
                    <measurement group_id="O2" value="9.5" lower_limit="5.2" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="4.9" upper_limit="19.8"/>
                    <measurement group_id="O2" value="8.5" lower_limit="5.1" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.4" upper_limit="11.2"/>
                    <measurement group_id="O2" value="8.3" lower_limit="5.3" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.1" upper_limit="8.8"/>
                    <measurement group_id="O2" value="7.6" lower_limit="4.7" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.6" upper_limit="9.7"/>
                    <measurement group_id="O2" value="5.4" lower_limit="3.1" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.5" upper_limit="7.6"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.3" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.4" upper_limit="10.3"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.7" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="3.0" upper_limit="12.5"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.6" upper_limit="7.4"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.8" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="2.6" lower_limit="1.3" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.6" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.4" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="4.7"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="2.9"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="2.8"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Institution Type</title>
        <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>University Hospital</title>
          </group>
          <group group_id="O2">
            <title>General Hospital</title>
          </group>
          <group group_id="O3">
            <title>Private Center</title>
          </group>
          <group group_id="O4">
            <title>Comprehensive Cancer Center</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Institution Type</title>
          <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1" lower_limit="65.5" upper_limit="87.0"/>
                    <measurement group_id="O2" value="73.4" lower_limit="56.3" upper_limit="85.5"/>
                    <measurement group_id="O3" value="90.6" lower_limit="80.8" upper_limit="95.7"/>
                    <measurement group_id="O4" value="62.4" lower_limit="39.8" upper_limit="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="38.6" upper_limit="88.0"/>
                    <measurement group_id="O2" value="65.2" lower_limit="46.5" upper_limit="80.1"/>
                    <measurement group_id="O3" value="82.3" lower_limit="57.1" upper_limit="94.2"/>
                    <measurement group_id="O4" value="41.8" lower_limit="10.1" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="58.2" upper_limit="82.2"/>
                    <measurement group_id="O2" value="67.3" lower_limit="52.9" upper_limit="79.0"/>
                    <measurement group_id="O3" value="63.5" lower_limit="42.5" upper_limit="80.3"/>
                    <measurement group_id="O4" value="62.0" lower_limit="39.4" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="27.7" upper_limit="56.0"/>
                    <measurement group_id="O2" value="58.4" lower_limit="41.3" upper_limit="73.7"/>
                    <measurement group_id="O3" value="52.6" lower_limit="36.9" upper_limit="67.8"/>
                    <measurement group_id="O4" value="67.3" lower_limit="50.3" upper_limit="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="18.8" upper_limit="42.6"/>
                    <measurement group_id="O2" value="39.1" lower_limit="26.0" upper_limit="54.0"/>
                    <measurement group_id="O3" value="35.2" lower_limit="17.8" upper_limit="57.7"/>
                    <measurement group_id="O4" value="53.3" lower_limit="23.3" upper_limit="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="10.2" upper_limit="32.2"/>
                    <measurement group_id="O2" value="16.1" lower_limit="8.0" upper_limit="29.7"/>
                    <measurement group_id="O3" value="13.5" lower_limit="5.7" upper_limit="28.6"/>
                    <measurement group_id="O4" value="29.9" lower_limit="15.5" upper_limit="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="12.4" upper_limit="48.0"/>
                    <measurement group_id="O2" value="13.4" lower_limit="7.9" upper_limit="21.9"/>
                    <measurement group_id="O3" value="4.8" lower_limit="1.6" upper_limit="13.2"/>
                    <measurement group_id="O4" value="7.8" lower_limit="3.2" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="4.5" upper_limit="32.4"/>
                    <measurement group_id="O2" value="7.0" lower_limit="2.6" upper_limit="17.6"/>
                    <measurement group_id="O3" value="8.8" lower_limit="3.2" upper_limit="21.7"/>
                    <measurement group_id="O4" value="8.1" lower_limit="2.1" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="2.0" upper_limit="14.3"/>
                    <measurement group_id="O2" value="11.5" lower_limit="6.3" upper_limit="20.2"/>
                    <measurement group_id="O3" value="11.9" lower_limit="4.5" upper_limit="27.7"/>
                    <measurement group_id="O4" value="4.0" lower_limit="1.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="2.4" upper_limit="16.8"/>
                    <measurement group_id="O2" value="11.6" lower_limit="7.3" upper_limit="18.0"/>
                    <measurement group_id="O3" value="6.1" lower_limit="2.5" upper_limit="14.5"/>
                    <measurement group_id="O4" value="2.5" lower_limit="0.6" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="3.2" upper_limit="16.2"/>
                    <measurement group_id="O2" value="7.9" lower_limit="3.5" upper_limit="16.8"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.0" upper_limit="11.8"/>
                    <measurement group_id="O4" value="6.1" lower_limit="1.4" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="2.0" upper_limit="12.5"/>
                    <measurement group_id="O2" value="4.6" lower_limit="1.9" upper_limit="10.5"/>
                    <measurement group_id="O3" value="5.2" lower_limit="1.6" upper_limit="15.6"/>
                    <measurement group_id="O4" value="3.0" lower_limit="0.6" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="5.2" lower_limit="2.7" upper_limit="9.6"/>
                    <measurement group_id="O3" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O4" value="9.7" lower_limit="3.5" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.4" upper_limit="7.7"/>
                    <measurement group_id="O2" value="9.0" lower_limit="3.6" upper_limit="20.6"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.4" upper_limit="11.6"/>
                    <measurement group_id="O4" value="1.7" lower_limit="0.4" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.4" upper_limit="7.6"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.2" upper_limit="8.3"/>
                    <measurement group_id="O3" value="2.9" lower_limit="0.8" upper_limit="10.8"/>
                    <measurement group_id="O4" value="1.6" lower_limit="0.3" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.3" upper_limit="6.5"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.6" upper_limit="8.8"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.2" upper_limit="7.2"/>
                    <measurement group_id="O4" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.0" upper_limit="8.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.6" upper_limit="5.6"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.7" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0.3" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.6" upper_limit="5.2"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.9" upper_limit="6.1"/>
                    <measurement group_id="O3" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O4" value="3.4" lower_limit="1.1" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.2" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.4" upper_limit="4.5"/>
                    <measurement group_id="O3" value="2.8" lower_limit="0.8" upper_limit="9.5"/>
                    <measurement group_id="O4" value="3.5" lower_limit="0.8" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O2" value="1.7" lower_limit="0.6" upper_limit="4.8"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.4" upper_limit="4.6"/>
                    <measurement group_id="O4" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O3" value="0.5" lower_limit="0.1" upper_limit="3.6"/>
                    <measurement group_id="O4" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Tumor Type</title>
        <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Breast Cancer</title>
          </group>
          <group group_id="O2">
            <title>Non-small Cell Lung Cancer</title>
          </group>
          <group group_id="O3">
            <title>Non-Hodgkin's Lymphoma</title>
          </group>
          <group group_id="O4">
            <title>Small Cell Lung Cancer</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Tumor Type</title>
          <description>For each participant, the investigator ranked the risk factors that they considered to be the most important factors that they considered when deciding whether to use G-CSF PP treatment or not.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set. Subgroup analyses were only performed in subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="182"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outcome of the overall FN risk assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="73.9" upper_limit="87.2"/>
                    <measurement group_id="O2" value="64.5" lower_limit="51.4" upper_limit="75.8"/>
                    <measurement group_id="O3" value="78.5" lower_limit="64.1" upper_limit="88.2"/>
                    <measurement group_id="O4" value="62.6" lower_limit="47.2" upper_limit="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="62.3" upper_limit="85.1"/>
                    <measurement group_id="O2" value="59.7" lower_limit="39.5" upper_limit="77.0"/>
                    <measurement group_id="O3" value="45.4" lower_limit="25.1" upper_limit="67.4"/>
                    <measurement group_id="O4" value="59.8" lower_limit="35.7" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" lower_limit="57.1" upper_limit="78.6"/>
                    <measurement group_id="O2" value="66.6" lower_limit="56.4" upper_limit="75.4"/>
                    <measurement group_id="O3" value="60.5" lower_limit="46.9" upper_limit="72.6"/>
                    <measurement group_id="O4" value="62.7" lower_limit="48.2" upper_limit="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="28.9" upper_limit="50.2"/>
                    <measurement group_id="O2" value="56.5" lower_limit="44.1" upper_limit="68.1"/>
                    <measurement group_id="O3" value="69.5" lower_limit="57.7" upper_limit="79.2"/>
                    <measurement group_id="O4" value="45.1" lower_limit="30.7" upper_limit="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="17.3" upper_limit="36.9"/>
                    <measurement group_id="O2" value="49.5" lower_limit="34.3" upper_limit="64.7"/>
                    <measurement group_id="O3" value="42.1" lower_limit="30.0" upper_limit="55.2"/>
                    <measurement group_id="O4" value="44.0" lower_limit="28.3" upper_limit="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="11.3" upper_limit="22.8"/>
                    <measurement group_id="O2" value="24.2" lower_limit="15.4" upper_limit="35.9"/>
                    <measurement group_id="O3" value="29.1" lower_limit="18.7" upper_limit="42.3"/>
                    <measurement group_id="O4" value="9.7" lower_limit="4.0" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of chemotherapy cycle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="5.8" upper_limit="17.9"/>
                    <measurement group_id="O2" value="16.1" lower_limit="7.8" upper_limit="30.1"/>
                    <measurement group_id="O3" value="16.7" lower_limit="8.4" upper_limit="30.4"/>
                    <measurement group_id="O4" value="14.5" lower_limit="6.2" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="4.5" upper_limit="17.3"/>
                    <measurement group_id="O2" value="7.2" lower_limit="3.5" upper_limit="14.1"/>
                    <measurement group_id="O3" value="18.1" lower_limit="7.5" upper_limit="37.7"/>
                    <measurement group_id="O4" value="13.1" lower_limit="6.7" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="4.1" upper_limit="14.0"/>
                    <measurement group_id="O2" value="12.7" lower_limit="6.3" upper_limit="23.7"/>
                    <measurement group_id="O3" value="10.3" lower_limit="5.1" upper_limit="19.9"/>
                    <measurement group_id="O4" value="10.4" lower_limit="3.6" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient lives far from clinic/healthcare resources</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4.1" upper_limit="13.9"/>
                    <measurement group_id="O2" value="8.9" lower_limit="4.7" upper_limit="16.4"/>
                    <measurement group_id="O3" value="8.2" lower_limit="4.2" upper_limit="15.4"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.3" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.9" upper_limit="7.9"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.9" upper_limit="8.4"/>
                    <measurement group_id="O3" value="15.0" lower_limit="7.1" upper_limit="29.1"/>
                    <measurement group_id="O4" value="7.9" lower_limit="4.1" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated compliance with the treatment plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="2.5" upper_limit="10.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.7" upper_limit="10.5"/>
                    <measurement group_id="O3" value="7.2" lower_limit="3.3" upper_limit="15.3"/>
                    <measurement group_id="O4" value="5.0" lower_limit="1.7" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of G-CSFs in general</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.9" upper_limit="8.5"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.2" upper_limit="6.0"/>
                    <measurement group_id="O3" value="5.4" lower_limit="2.1" upper_limit="13.1"/>
                    <measurement group_id="O4" value="5.2" lower_limit="2.1" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local access to reimbursed G-CSF PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.1" upper_limit="11.2"/>
                    <measurement group_id="O2" value="6.9" lower_limit="2.6" upper_limit="16.6"/>
                    <measurement group_id="O3" value="5.7" lower_limit="2.3" upper_limit="13.4"/>
                    <measurement group_id="O4" value="7.4" lower_limit="2.6" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/caregiver/nurse support to the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.2" upper_limit="5.9"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.6" upper_limit="6.8"/>
                    <measurement group_id="O3" value="4.5" lower_limit="1.8" upper_limit="11.0"/>
                    <measurement group_id="O4" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired vs employed/active status of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.6" upper_limit="6.1"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.1" upper_limit="6.1"/>
                    <measurement group_id="O3" value="4.1" lower_limit="1.9" upper_limit="8.4"/>
                    <measurement group_id="O4" value="3.9" lower_limit="1.2" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="4.2" lower_limit="2.0" upper_limit="8.5"/>
                    <measurement group_id="O3" value="4.9" lower_limit="1.9" upper_limit="12.0"/>
                    <measurement group_id="O4" value="1.8" lower_limit="0.4" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safety risk of intensive chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.3" upper_limit="5.3"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.2" upper_limit="3.3"/>
                    <measurement group_id="O3" value="3.5" lower_limit="1.5" upper_limit="8.2"/>
                    <measurement group_id="O4" value="2.6" lower_limit="0.8" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wait and see approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.1" upper_limit="4.8"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.3" upper_limit="7.4"/>
                    <measurement group_id="O3" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O4" value="2.9" lower_limit="0.9" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private health insurance of the patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="2.1" lower_limit="0.8" upper_limit="5.6"/>
                    <measurement group_id="O3" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O4" value="1.8" lower_limit="0.4" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O3" value="0.7" lower_limit="0.1" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Clinical Specialty</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rankt the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group. Subgroup analyses were performed where a subgroup contained at least 40 investigators. Results are reported for medical oncologists as this was the only specialty that contained at least 40 investigators.</description>
        <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators (PASI); analysis was only performed for subgroups containing at least 40 investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Oncologist</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Clinical Specialty</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rankt the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group. Subgroup analyses were performed where a subgroup contained at least 40 investigators. Results are reported for medical oncologists as this was the only specialty that contained at least 40 investigators.</description>
          <population>Primary analysis set - investigators (PASI); analysis was only performed for subgroups containing at least 40 investigators.</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="662"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" lower_limit="80.6" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="73.2" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" lower_limit="62.8" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="61.3" upper_limit="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="58.3" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" lower_limit="57.6" upper_limit="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="53.7" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="53.8" upper_limit="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="53.6" upper_limit="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" lower_limit="52.7" upper_limit="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="44.4" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="45.1" upper_limit="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="44.1" upper_limit="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" lower_limit="41.8" upper_limit="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="37.8" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="34.0" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="29.8" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="31.5" upper_limit="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" lower_limit="27.6" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="21.1" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="20.5" upper_limit="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="2.2" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Number of Years in Clinical Practice in Oncology / Hematology</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators (PASI); analysis was only performed for subgroups containing at least 40 investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>≤ 10 Years</title>
          </group>
          <group group_id="O2">
            <title>&gt; 10 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Number of Years in Clinical Practice in Oncology / Hematology</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the risk factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set - investigators (PASI); analysis was only performed for subgroups containing at least 40 investigators.</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="687"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="75.6" upper_limit="96.0"/>
                    <measurement group_id="O2" value="87.4" lower_limit="79.3" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="74.5" upper_limit="96.1"/>
                    <measurement group_id="O2" value="79.6" lower_limit="70.9" upper_limit="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="57.0" upper_limit="84.7"/>
                    <measurement group_id="O2" value="67.3" lower_limit="56.1" upper_limit="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" lower_limit="54.8" upper_limit="83.8"/>
                    <measurement group_id="O2" value="76.1" lower_limit="67.3" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="52.8" upper_limit="81.4"/>
                    <measurement group_id="O2" value="74.9" lower_limit="64.3" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" lower_limit="52.3" upper_limit="81.7"/>
                    <measurement group_id="O2" value="71.1" lower_limit="61.7" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="37.4" upper_limit="71.2"/>
                    <measurement group_id="O2" value="68.1" lower_limit="57.4" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="36.8" upper_limit="67.0"/>
                    <measurement group_id="O2" value="67.0" lower_limit="57.0" upper_limit="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="43.4" upper_limit="76.0"/>
                    <measurement group_id="O2" value="61.5" lower_limit="51.3" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="47.3" upper_limit="79.3"/>
                    <measurement group_id="O2" value="63.8" lower_limit="53.9" upper_limit="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="41.5" upper_limit="73.9"/>
                    <measurement group_id="O2" value="62.7" lower_limit="50.9" upper_limit="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="44.2" upper_limit="75.2"/>
                    <measurement group_id="O2" value="63.4" lower_limit="52.5" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="33.0" upper_limit="63.2"/>
                    <measurement group_id="O2" value="52.2" lower_limit="41.0" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="28.1" upper_limit="66.4"/>
                    <measurement group_id="O2" value="49.3" lower_limit="39.7" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="26.7" upper_limit="65.3"/>
                    <measurement group_id="O2" value="48.8" lower_limit="38.2" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" lower_limit="24.7" upper_limit="56.7"/>
                    <measurement group_id="O2" value="47.3" lower_limit="37.5" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="16.7" upper_limit="48.1"/>
                    <measurement group_id="O2" value="40.5" lower_limit="29.9" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="20.5" upper_limit="49.2"/>
                    <measurement group_id="O2" value="43.5" lower_limit="34.4" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="27.8" upper_limit="61.6"/>
                    <measurement group_id="O2" value="41.4" lower_limit="31.3" upper_limit="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="11.9" upper_limit="39.5"/>
                    <measurement group_id="O2" value="24.5" lower_limit="16.3" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="15.6" upper_limit="42.8"/>
                    <measurement group_id="O2" value="25.8" lower_limit="17.8" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1.1" upper_limit="19.0"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.4" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.2" upper_limit="15.9"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.8" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Institution Type</title>
        <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>Assessed at Baseline, prior to participant enrolment.</time_frame>
        <population>Primary analysis set - investigators (PASI); analysis was only performed for subgroups containing at least 40 investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>University Hospital</title>
          </group>
          <group group_id="O2">
            <title>General Hospital</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Institution Type</title>
          <description>During the baseline investigator assessment (prior to identification of participants), investigators were provided a list of risk factors on a source document worksheet, and asked to rank the factors that they considered to be the most important when assessing overall FN risk. To account for the expected correlation between investigators at the same sites, two-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals. ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set - investigators (PASI); analysis was only performed for subgroups containing at least 40 investigators.</population>
          <units>percentage of investigators</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Investigators</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Investigators</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="75.6" upper_limit="97.2"/>
                    <measurement group_id="O2" value="87.0" lower_limit="72.9" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="73.3" upper_limit="94.7"/>
                    <measurement group_id="O2" value="78.3" lower_limit="61.1" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="54.1" upper_limit="86.2"/>
                    <measurement group_id="O2" value="62.9" lower_limit="45.4" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="64.8" upper_limit="92.9"/>
                    <measurement group_id="O2" value="79.4" lower_limit="63.0" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" lower_limit="53.5" upper_limit="85.7"/>
                    <measurement group_id="O2" value="77.2" lower_limit="55.9" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" lower_limit="57.3" upper_limit="87.1"/>
                    <measurement group_id="O2" value="72.0" lower_limit="53.0" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" lower_limit="42.3" upper_limit="72.9"/>
                    <measurement group_id="O2" value="74.1" lower_limit="57.4" upper_limit="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="54.7" upper_limit="79.5"/>
                    <measurement group_id="O2" value="62.0" lower_limit="41.1" upper_limit="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="38.1" upper_limit="76.5"/>
                    <measurement group_id="O2" value="64.5" lower_limit="47.3" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8" lower_limit="57.9" upper_limit="88.8"/>
                    <measurement group_id="O2" value="61.5" lower_limit="41.2" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="58.7" upper_limit="90.2"/>
                    <measurement group_id="O2" value="63.0" lower_limit="44.0" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" lower_limit="44.8" upper_limit="81.4"/>
                    <measurement group_id="O2" value="60.9" lower_limit="45.4" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" lower_limit="30.9" upper_limit="68.4"/>
                    <measurement group_id="O2" value="47.8" lower_limit="33.2" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="30.9" upper_limit="63.1"/>
                    <measurement group_id="O2" value="47.0" lower_limit="26.7" upper_limit="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="31.1" upper_limit="71.3"/>
                    <measurement group_id="O2" value="50.8" lower_limit="34.7" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="26.0" upper_limit="57.3"/>
                    <measurement group_id="O2" value="55.6" lower_limit="37.9" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" lower_limit="29.5" upper_limit="60.9"/>
                    <measurement group_id="O2" value="39.0" lower_limit="20.8" upper_limit="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="19.6" upper_limit="49.0"/>
                    <measurement group_id="O2" value="39.0" lower_limit="23.7" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" lower_limit="29.1" upper_limit="63.8"/>
                    <measurement group_id="O2" value="34.2" lower_limit="18.0" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="9.5" upper_limit="35.0"/>
                    <measurement group_id="O2" value="10.2" lower_limit="3.1" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="11.2" upper_limit="37.8"/>
                    <measurement group_id="O2" value="23.1" lower_limit="10.7" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.8" upper_limit="14.6"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.3" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.8" upper_limit="14.1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.3" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Country</title>
        <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set; analysis only includes subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Poland</title>
          </group>
          <group group_id="O2">
            <title>Greece</title>
          </group>
          <group group_id="O3">
            <title>Romania</title>
          </group>
          <group group_id="O4">
            <title>France</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Country</title>
          <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set; analysis only includes subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="49.6" upper_limit="95.1"/>
                    <measurement group_id="O2" value="96.3" lower_limit="80.7" upper_limit="99.4"/>
                    <measurement group_id="O3" value="98.2" lower_limit="90.4" upper_limit="99.7"/>
                    <measurement group_id="O4" value="88.3" lower_limit="59.0" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" lower_limit="28.1" upper_limit="91.9"/>
                    <measurement group_id="O2" value="61.4" lower_limit="18.3" upper_limit="91.8"/>
                    <measurement group_id="O3" value="95.3" lower_limit="82.6" upper_limit="98.9"/>
                    <measurement group_id="O4" value="67.9" lower_limit="44.2" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="40.9" upper_limit="98.0"/>
                    <measurement group_id="O2" value="44.7" lower_limit="21.4" upper_limit="70.6"/>
                    <measurement group_id="O3" value="91.0" lower_limit="62.9" upper_limit="98.4"/>
                    <measurement group_id="O4" value="62.7" lower_limit="24.1" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" lower_limit="14.3" upper_limit="82.8"/>
                    <measurement group_id="O2" value="39.5" lower_limit="17.9" upper_limit="66.0"/>
                    <measurement group_id="O3" value="69.4" lower_limit="45.6" upper_limit="86.0"/>
                    <measurement group_id="O4" value="24.3" lower_limit="11.4" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" lower_limit="27.8" upper_limit="72.4"/>
                    <measurement group_id="O2" value="45.1" lower_limit="24.7" upper_limit="67.3"/>
                    <measurement group_id="O3" value="33.0" lower_limit="19.6" upper_limit="50.0"/>
                    <measurement group_id="O4" value="13.5" lower_limit="5.2" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="6.5" upper_limit="33.7"/>
                    <measurement group_id="O2" value="24.7" lower_limit="12.2" upper_limit="43.5"/>
                    <measurement group_id="O3" value="52.0" lower_limit="33.0" upper_limit="70.4"/>
                    <measurement group_id="O4" value="16.9" lower_limit="3.9" upper_limit="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4" lower_limit="29.8" upper_limit="81.1"/>
                    <measurement group_id="O2" value="29.3" lower_limit="15.2" upper_limit="48.9"/>
                    <measurement group_id="O3" value="23.4" lower_limit="8.0" upper_limit="51.9"/>
                    <measurement group_id="O4" value="19.4" lower_limit="10.6" upper_limit="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="15.0" upper_limit="48.3"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.1" upper_limit="13.7"/>
                    <measurement group_id="O3" value="38.0" lower_limit="18.3" upper_limit="62.6"/>
                    <measurement group_id="O4" value="8.7" lower_limit="2.8" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="11.7" upper_limit="27.5"/>
                    <measurement group_id="O2" value="18.2" lower_limit="11.7" upper_limit="27.1"/>
                    <measurement group_id="O3" value="29.9" lower_limit="14.5" upper_limit="51.9"/>
                    <measurement group_id="O4" value="6.4" lower_limit="2.0" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="10.1" upper_limit="31.4"/>
                    <measurement group_id="O2" value="7.9" lower_limit="2.3" upper_limit="23.3"/>
                    <measurement group_id="O3" value="27.7" lower_limit="11.1" upper_limit="54.1"/>
                    <measurement group_id="O4" value="7.4" lower_limit="2.4" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="1.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="19.2" lower_limit="6.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="11.6" lower_limit="2.9" upper_limit="36.7"/>
                    <measurement group_id="O4" value="26.8" lower_limit="15.0" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="8.2" upper_limit="23.4"/>
                    <measurement group_id="O2" value="12.7" lower_limit="7.1" upper_limit="21.7"/>
                    <measurement group_id="O3" value="28.8" lower_limit="15.0" upper_limit="48.2"/>
                    <measurement group_id="O4" value="10.7" lower_limit="5.4" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="4.3" upper_limit="18.0"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.5" upper_limit="11.6"/>
                    <measurement group_id="O3" value="12.6" lower_limit="4.9" upper_limit="28.7"/>
                    <measurement group_id="O4" value="10.7" lower_limit="4.9" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="1.4" upper_limit="12.5"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O3" value="12.0" lower_limit="1.4" upper_limit="57.1"/>
                    <measurement group_id="O4" value="3.5" lower_limit="0.9" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.6" upper_limit="5.8"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.7" upper_limit="10.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="1.8" upper_limit="13.0"/>
                    <measurement group_id="O4" value="4.2" lower_limit="1.5" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="1.2" upper_limit="15.2"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="7.3" lower_limit="3.2" upper_limit="15.9"/>
                    <measurement group_id="O4" value="4.0" lower_limit="1.2" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="8.0" lower_limit="2.1" upper_limit="26.3"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.6" upper_limit="10.5"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.5" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="2.5" upper_limit="10.6"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.2" upper_limit="10.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="1.0" upper_limit="9.3"/>
                    <measurement group_id="O4" value="1.6" lower_limit="0.4" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.2" upper_limit="6.7"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.9" upper_limit="8.5"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.6" upper_limit="15.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.1" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.9" upper_limit="5.9"/>
                    <measurement group_id="O2" value="5.7" lower_limit="2.2" upper_limit="13.6"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.1" upper_limit="5.4"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.5" upper_limit="5.4"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.1" upper_limit="4.3"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.4" upper_limit="6.5"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.1" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.4" upper_limit="9.0"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.8" upper_limit="7.8"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.2" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.8" upper_limit="6.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O4" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Clinical Specialty</title>
        <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Oncologist</title>
          </group>
          <group group_id="O2">
            <title>Hematologist</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Clinical Specialty</title>
          <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="662"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="87.5" upper_limit="96.3"/>
                    <measurement group_id="O2" value="93.6" lower_limit="84.4" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="59.0" upper_limit="83.0"/>
                    <measurement group_id="O2" value="81.4" lower_limit="59.4" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" lower_limit="58.0" upper_limit="82.6"/>
                    <measurement group_id="O2" value="27.5" lower_limit="11.0" upper_limit="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="37.8" upper_limit="60.3"/>
                    <measurement group_id="O2" value="42.3" lower_limit="26.3" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="32.4" upper_limit="50.1"/>
                    <measurement group_id="O2" value="55.5" lower_limit="42.2" upper_limit="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="22.5" upper_limit="39.7"/>
                    <measurement group_id="O2" value="39.0" lower_limit="23.7" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="21.1" upper_limit="41.1"/>
                    <measurement group_id="O2" value="28.8" lower_limit="18.8" upper_limit="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="14.6" upper_limit="32.3"/>
                    <measurement group_id="O2" value="13.6" lower_limit="8.0" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="10.2" upper_limit="18.3"/>
                    <measurement group_id="O2" value="27.2" lower_limit="17.2" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="10.5" upper_limit="21.3"/>
                    <measurement group_id="O2" value="24.7" lower_limit="14.2" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="10.4" upper_limit="27.5"/>
                    <measurement group_id="O2" value="10.0" lower_limit="4.5" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="11.3" upper_limit="21.3"/>
                    <measurement group_id="O2" value="14.4" lower_limit="9.2" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="4.7" upper_limit="11.1"/>
                    <measurement group_id="O2" value="13.2" lower_limit="6.7" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="4.0" upper_limit="14.6"/>
                    <measurement group_id="O2" value="9.4" lower_limit="3.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.6" upper_limit="6.3"/>
                    <measurement group_id="O2" value="11.9" lower_limit="5.6" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.1" upper_limit="6.1"/>
                    <measurement group_id="O2" value="5.7" lower_limit="2.5" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.2" upper_limit="3.7"/>
                    <measurement group_id="O2" value="20.8" lower_limit="12.2" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.1" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="9.1" lower_limit="4.3" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.4" upper_limit="4.0"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.3" upper_limit="4.4"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.8" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.6" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.5" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Number of Years in Clinical Practice in Oncology / Hematology</title>
        <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>≤ 10 Years</title>
          </group>
          <group group_id="O2">
            <title>&gt; 10 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Number of Years in Clinical Practice in Oncology / Hematology</title>
          <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" lower_limit="80.2" upper_limit="96.6"/>
                    <measurement group_id="O2" value="92.6" lower_limit="87.5" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="41.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="76.6" lower_limit="65.0" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" lower_limit="32.8" upper_limit="76.5"/>
                    <measurement group_id="O2" value="60.1" lower_limit="45.9" upper_limit="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" lower_limit="22.6" upper_limit="49.6"/>
                    <measurement group_id="O2" value="45.9" lower_limit="35.3" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="24.1" upper_limit="48.9"/>
                    <measurement group_id="O2" value="41.5" lower_limit="33.3" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="17.7" upper_limit="38.3"/>
                    <measurement group_id="O2" value="32.3" lower_limit="23.8" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="14.1" upper_limit="36.3"/>
                    <measurement group_id="O2" value="31.1" lower_limit="23.8" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="7.6" upper_limit="20.0"/>
                    <measurement group_id="O2" value="21.1" lower_limit="14.1" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="9.9" upper_limit="21.4"/>
                    <measurement group_id="O2" value="16.2" lower_limit="12.4" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="7.0" upper_limit="21.7"/>
                    <measurement group_id="O2" value="15.5" lower_limit="11.0" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="8.2" upper_limit="28.3"/>
                    <measurement group_id="O2" value="15.1" lower_limit="9.7" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="15.8" lower_limit="11.9" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.5" upper_limit="11.0"/>
                    <measurement group_id="O2" value="9.2" lower_limit="6.5" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="2.2" upper_limit="11.7"/>
                    <measurement group_id="O2" value="7.7" lower_limit="4.3" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.1" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.8" upper_limit="5.4"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.3" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.5" upper_limit="6.7"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.8" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.1" upper_limit="7.1"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.8" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.7" upper_limit="4.7"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.8" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.8" upper_limit="8.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.2" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.2" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.1" upper_limit="6.6"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="4.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Institution Type</title>
        <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>University Hospital</title>
          </group>
          <group group_id="O2">
            <title>General Hospital</title>
          </group>
          <group group_id="O3">
            <title>Private Center</title>
          </group>
          <group group_id="O4">
            <title>Comprehensive Cancer Center</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Institution Type</title>
          <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="87.7" upper_limit="98.4"/>
                    <measurement group_id="O2" value="92.7" lower_limit="83.1" upper_limit="97.0"/>
                    <measurement group_id="O3" value="91.9" lower_limit="76.1" upper_limit="97.6"/>
                    <measurement group_id="O4" value="86.1" lower_limit="68.3" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" lower_limit="44.8" upper_limit="82.5"/>
                    <measurement group_id="O2" value="81.6" lower_limit="60.1" upper_limit="92.9"/>
                    <measurement group_id="O3" value="68.7" lower_limit="42.0" upper_limit="86.9"/>
                    <measurement group_id="O4" value="74.4" lower_limit="38.9" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="27.6" upper_limit="74.8"/>
                    <measurement group_id="O2" value="64.0" lower_limit="46.5" upper_limit="78.5"/>
                    <measurement group_id="O3" value="74.8" lower_limit="46.8" upper_limit="90.9"/>
                    <measurement group_id="O4" value="54.6" lower_limit="12.0" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="21.7" upper_limit="56.0"/>
                    <measurement group_id="O2" value="51.4" lower_limit="38.7" upper_limit="63.9"/>
                    <measurement group_id="O3" value="36.9" lower_limit="20.4" upper_limit="57.2"/>
                    <measurement group_id="O4" value="44.8" lower_limit="16.3" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="20.1" upper_limit="50.2"/>
                    <measurement group_id="O2" value="37.8" lower_limit="25.6" upper_limit="51.9"/>
                    <measurement group_id="O3" value="45.8" lower_limit="31.5" upper_limit="60.9"/>
                    <measurement group_id="O4" value="50.3" lower_limit="29.9" upper_limit="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="19.0" upper_limit="48.4"/>
                    <measurement group_id="O2" value="33.7" lower_limit="21.1" upper_limit="49.0"/>
                    <measurement group_id="O3" value="33.1" lower_limit="19.9" upper_limit="49.5"/>
                    <measurement group_id="O4" value="17.2" lower_limit="8.0" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="12.9" upper_limit="31.2"/>
                    <measurement group_id="O2" value="31.7" lower_limit="19.9" upper_limit="46.4"/>
                    <measurement group_id="O3" value="29.3" lower_limit="15.2" upper_limit="49.1"/>
                    <measurement group_id="O4" value="42.1" lower_limit="21.5" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="7.4" upper_limit="27.9"/>
                    <measurement group_id="O2" value="15.8" lower_limit="8.2" upper_limit="28.4"/>
                    <measurement group_id="O3" value="22.6" lower_limit="9.7" upper_limit="44.4"/>
                    <measurement group_id="O4" value="25.4" lower_limit="12.1" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="8.6" upper_limit="22.9"/>
                    <measurement group_id="O2" value="13.9" lower_limit="9.3" upper_limit="20.1"/>
                    <measurement group_id="O3" value="17.8" lower_limit="9.8" upper_limit="30.1"/>
                    <measurement group_id="O4" value="17.3" lower_limit="10.6" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="10.5" upper_limit="36.2"/>
                    <measurement group_id="O2" value="12.5" lower_limit="7.4" upper_limit="20.4"/>
                    <measurement group_id="O3" value="10.5" lower_limit="4.4" upper_limit="23.0"/>
                    <measurement group_id="O4" value="22.1" lower_limit="12.9" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="4.4" upper_limit="19.0"/>
                    <measurement group_id="O2" value="15.4" lower_limit="7.6" upper_limit="28.6"/>
                    <measurement group_id="O3" value="37.6" lower_limit="22.2" upper_limit="55.9"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.5" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="9.5" upper_limit="25.3"/>
                    <measurement group_id="O2" value="13.0" lower_limit="9.2" upper_limit="18.0"/>
                    <measurement group_id="O3" value="12.8" lower_limit="7.0" upper_limit="22.4"/>
                    <measurement group_id="O4" value="18.5" lower_limit="6.5" upper_limit="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="4.2" upper_limit="15.8"/>
                    <measurement group_id="O2" value="11.2" lower_limit="6.2" upper_limit="19.4"/>
                    <measurement group_id="O3" value="5.4" lower_limit="2.4" upper_limit="11.6"/>
                    <measurement group_id="O4" value="5.9" lower_limit="2.6" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="3.9" upper_limit="25.1"/>
                    <measurement group_id="O2" value="6.3" lower_limit="2.4" upper_limit="15.5"/>
                    <measurement group_id="O3" value="4.1" lower_limit="1.0" upper_limit="15.4"/>
                    <measurement group_id="O4" value="7.7" lower_limit="1.9" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="3.2" upper_limit="11.5"/>
                    <measurement group_id="O2" value="7.3" lower_limit="3.5" upper_limit="14.6"/>
                    <measurement group_id="O3" value="2.9" lower_limit="1.2" upper_limit="7.0"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.9" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="3.0" lower_limit="1.3" upper_limit="6.5"/>
                    <measurement group_id="O3" value="5.6" lower_limit="2.7" upper_limit="11.3"/>
                    <measurement group_id="O4" value="3.9" lower_limit="0.9" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="2.9" upper_limit="13.8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.3" upper_limit="10.7"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1.2" upper_limit="10.5"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.4" upper_limit="6.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.4" upper_limit="5.6"/>
                    <measurement group_id="O3" value="5.2" lower_limit="2.6" upper_limit="10.0"/>
                    <measurement group_id="O4" value="4.4" lower_limit="1.9" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="2.1" upper_limit="10.8"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="3.3" lower_limit="1.1" upper_limit="9.3"/>
                    <measurement group_id="O4" value="2.9" lower_limit="1.1" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.5" upper_limit="4.3"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.8" upper_limit="5.4"/>
                    <measurement group_id="O3" value="3.1" lower_limit="1.3" upper_limit="7.3"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.9" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="1.8" lower_limit="0.6" upper_limit="5.4"/>
                    <measurement group_id="O3" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O4" value="3.0" lower_limit="1.1" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.4" upper_limit="9.1"/>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O3" value="2.4" lower_limit="0.9" upper_limit="6.6"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.3" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Not applicable since the statistical model was not applied to calculate confidence limits for outcomes with no variation in response.</measurement>
                    <measurement group_id="O2" value="1.3" lower_limit="0.5" upper_limit="3.8"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.1" upper_limit="4.8"/>
                    <measurement group_id="O4" value="1.7" lower_limit="0.5" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Tumor Type</title>
        <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
        <time_frame>At enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Breast Cancer</title>
          </group>
          <group group_id="O2">
            <title>Non-small Cell Lung Cancer</title>
          </group>
          <group group_id="O3">
            <title>Non-Hodgkin's Lymphoma</title>
          </group>
          <group group_id="O4">
            <title>Small Cell Lung Cancer</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Tumor Type</title>
          <description>Investigators ranked the risk factors they considered to be the most important when assessing the overall risk of febrile neutopenia for each participant. Only historical patient information recorded before the beginning of chemotherapy treatment was collected in this study.
To account for the expected correlation between participants with the same investigators and between investigators at the same sites, three-level, empty (no explanatory variables) multilevel models were used in the estimation of the percentages and 95% confidence intervals.
ECOG = Eastern Cooperative Oncology Group.</description>
          <population>Primary analysis set; analysis only included subgroups with at least 100 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="182"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemotherapy agents in the backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="88.9" upper_limit="96.6"/>
                    <measurement group_id="O2" value="85.8" lower_limit="71.6" upper_limit="93.5"/>
                    <measurement group_id="O3" value="90.6" lower_limit="81.8" upper_limit="95.4"/>
                    <measurement group_id="O4" value="80.5" lower_limit="62.0" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" lower_limit="49.4" upper_limit="77.8"/>
                    <measurement group_id="O2" value="75.9" lower_limit="58.2" upper_limit="87.7"/>
                    <measurement group_id="O3" value="77.4" lower_limit="59.6" upper_limit="88.8"/>
                    <measurement group_id="O4" value="64.7" lower_limit="50.2" upper_limit="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guidelines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="55.5" upper_limit="78.9"/>
                    <measurement group_id="O2" value="62.7" lower_limit="43.2" upper_limit="78.8"/>
                    <measurement group_id="O3" value="43.2" lower_limit="23.2" upper_limit="65.7"/>
                    <measurement group_id="O4" value="56.3" lower_limit="33.4" upper_limit="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="28.3" upper_limit="50.2"/>
                    <measurement group_id="O2" value="57.7" lower_limit="42.1" upper_limit="72.0"/>
                    <measurement group_id="O3" value="39.7" lower_limit="26.6" upper_limit="54.4"/>
                    <measurement group_id="O4" value="64.7" lower_limit="36.7" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="23.5" upper_limit="41.3"/>
                    <measurement group_id="O2" value="42.3" lower_limit="30.3" upper_limit="55.3"/>
                    <measurement group_id="O3" value="56.9" lower_limit="45.9" upper_limit="67.2"/>
                    <measurement group_id="O4" value="33.5" lower_limit="19.3" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="23.9" upper_limit="45.7"/>
                    <measurement group_id="O2" value="25.2" lower_limit="16.4" upper_limit="36.7"/>
                    <measurement group_id="O3" value="35.1" lower_limit="23.4" upper_limit="48.9"/>
                    <measurement group_id="O4" value="22.2" lower_limit="11.8" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG/Karnofsky performance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="13.8" upper_limit="30.8"/>
                    <measurement group_id="O2" value="40.7" lower_limit="27.8" upper_limit="55.0"/>
                    <measurement group_id="O3" value="32.6" lower_limit="24.0" upper_limit="42.5"/>
                    <measurement group_id="O4" value="37.7" lower_limit="24.1" upper_limit="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female gender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="22.5" upper_limit="48.5"/>
                    <measurement group_id="O2" value="8.2" lower_limit="4.9" upper_limit="13.4"/>
                    <measurement group_id="O3" value="13.5" lower_limit="8.2" upper_limit="21.3"/>
                    <measurement group_id="O4" value="6.8" lower_limit="2.7" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="7.0" upper_limit="15.9"/>
                    <measurement group_id="O2" value="18.0" lower_limit="12.5" upper_limit="25.4"/>
                    <measurement group_id="O3" value="25.0" lower_limit="17.0" upper_limit="35.1"/>
                    <measurement group_id="O4" value="17.8" lower_limit="10.8" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline laboratory values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="8.2" upper_limit="20.5"/>
                    <measurement group_id="O2" value="15.3" lower_limit="9.4" upper_limit="23.9"/>
                    <measurement group_id="O3" value="21.9" lower_limit="14.4" upper_limit="31.9"/>
                    <measurement group_id="O4" value="10.5" lower_limit="4.5" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal experience of chemotherapy regimen risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="13.7" upper_limit="31.8"/>
                    <measurement group_id="O2" value="16.2" lower_limit="8.0" upper_limit="29.8"/>
                    <measurement group_id="O3" value="14.4" lower_limit="7.1" upper_limit="27.0"/>
                    <measurement group_id="O4" value="22.6" lower_limit="12.8" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="7.6" upper_limit="19.5"/>
                    <measurement group_id="O2" value="17.0" lower_limit="11.7" upper_limit="24.2"/>
                    <measurement group_id="O3" value="14.3" lower_limit="9.7" upper_limit="20.4"/>
                    <measurement group_id="O4" value="15.1" lower_limit="9.4" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutritional status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.3" upper_limit="7.6"/>
                    <measurement group_id="O2" value="13.0" lower_limit="7.8" upper_limit="20.8"/>
                    <measurement group_id="O3" value="14.3" lower_limit="7.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="11.0" lower_limit="5.9" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned relative dose intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="3.4" upper_limit="13.9"/>
                    <measurement group_id="O2" value="5.7" lower_limit="2.4" upper_limit="13.0"/>
                    <measurement group_id="O3" value="10.2" lower_limit="4.4" upper_limit="21.9"/>
                    <measurement group_id="O4" value="10.8" lower_limit="6.0" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medications taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.2" upper_limit="6.9"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.6" upper_limit="6.3"/>
                    <measurement group_id="O3" value="11.1" lower_limit="6.0" upper_limit="19.9"/>
                    <measurement group_id="O4" value="5.5" lower_limit="2.2" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prior FN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.2" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.6" upper_limit="6.3"/>
                    <measurement group_id="O3" value="7.0" lower_limit="3.3" upper_limit="14.2"/>
                    <measurement group_id="O4" value="2.7" lower_limit="0.7" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented bone marrow involvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.7" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.8" upper_limit="4.8"/>
                    <measurement group_id="O3" value="19.4" lower_limit="11.8" upper_limit="30.3"/>
                    <measurement group_id="O4" value="1.7" lower_limit="0.4" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior radiotherapy involving bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.3" upper_limit="6.6"/>
                    <measurement group_id="O2" value="5.9" lower_limit="3.2" upper_limit="10.7"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.8" upper_limit="5.8"/>
                    <measurement group_id="O4" value="3.4" lower_limit="1.2" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="3.6" lower_limit="1.8" upper_limit="6.9"/>
                    <measurement group_id="O3" value="8.8" lower_limit="4.9" upper_limit="15.3"/>
                    <measurement group_id="O4" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.4" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.3" upper_limit="6.3"/>
                    <measurement group_id="O3" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O4" value="10.3" lower_limit="5.4" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.3" upper_limit="5.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.4" upper_limit="4.1"/>
                    <measurement group_id="O3" value="3.5" lower_limit="1.4" upper_limit="8.3"/>
                    <measurement group_id="O4" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other patient related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="2.6" lower_limit="0.9" upper_limit="7.1"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.0" upper_limit="11.5"/>
                    <measurement group_id="O4" value="2.6" lower_limit="0.8" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease/treatment related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O2" value="NA">Not applicable due to lack of convergence in the statistical model.</measurement>
                    <measurement group_id="O3" value="1.1" lower_limit="0.3" upper_limit="4.3"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.6" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Investigator-assessed FN Risk at or Above the Investigator Self-reported FN-risk Intervention Threshold Who Were Planned to Receive G-CSF PP</title>
        <description>At Baseline investigators recorded the FN risk threshold score at which they would use G-CSF PP in their usual clinical practice. For each enrolled participant, the investigator documented their final estimated FN risk score as a percentage based on the participant’s medical history and standard of care assessments (their routine practice for assessing this risk), and a decision as to whether G-CSF PP would be administered in Cycle 1.</description>
        <time_frame>At Baseline and at enrolment, prior to chemotherapy initiation.</time_frame>
        <population>Primary analysis set, participants with investigator-assessed FN risk at or above the investigator FN-risk intervention threshold</population>
        <group_list>
          <group group_id="O1">
            <title>At or Above Investigator Threshold</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Investigator-assessed FN Risk at or Above the Investigator Self-reported FN-risk Intervention Threshold Who Were Planned to Receive G-CSF PP</title>
          <description>At Baseline investigators recorded the FN risk threshold score at which they would use G-CSF PP in their usual clinical practice. For each enrolled participant, the investigator documented their final estimated FN risk score as a percentage based on the participant’s medical history and standard of care assessments (their routine practice for assessing this risk), and a decision as to whether G-CSF PP would be administered in Cycle 1.</description>
          <population>Primary analysis set, participants with investigator-assessed FN risk at or above the investigator FN-risk intervention threshold</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events were not collected for this observational protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Enrolled Patients</title>
          <description>Participants with cancer who were planning to receive standard dose chemotherapy regimens with a documented intermediate risk (10% to 20%) of febrile neutropenia (FN).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

